Fusion Antibodies Plc (FAB.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Sales | 1,965 | 1,136 | 2,901 | 4,799 | 4,165 |
| Cost of Goods | 1,535 | 1,181 | 2,327 | 2,333 | 2,141 |
| Gross Profit | 430 | -45 | 574 | 2,466 | 2,024 |
| Operating Expenses | 2,209 | 2,242 | 3,432 | 3,791 | 3,273 |
| Operating Income | -1,779 | -2,287 | -2,858 | -1,325 | -1,249 |
| Interest Expense | 3 | 5 | 4 | 9 | 18 |
| Other Income | 5 | 3 | 3 | 1 | 3 |
| Pre-tax Income | -1,777 | -2,289 | -2,859 | -1,333 | -1,264 |
| Income Tax | -64 | -63 | -263 | -133 | 1,635 |
| Net Income Continuous | -1,713 | -2,226 | -2,596 | -1,200 | -2,899 |
| Net Income | $-1,713 | $-2,226 | $-2,596 | $-1,200 | $-2,899 |
| EPS Basic Total Ops | -0.02 | -0.04 | -0.10 | -0.05 | -0.11 |
| EPS Basic Continuous Ops | -0.02 | -0.04 | -0.10 | -0.05 | -0.11 |
| EPS Diluted Total Ops | -0.02 | -0.04 | -0.10 | -0.05 | -0.11 |
| EPS Diluted Continuous Ops | -0.02 | -0.04 | -0.10 | -0.05 | -0.11 |
| EBITDA(a) | $-1,669 | $-2,064 | $-2,483 | $-573 | $-532 |